The first analysis of oocyte transcriptomes, awarded at the 33rd SEF National Congress

The first analysis of oocyte transcriptomes, awarded at the 33rd SEF National Congress

A study led by Dr Francisca Martínez of the Reproductive Medicine Unit of Dexeus Mujer analysed oocyte transcriptomes after two different LH suppression protocols in the same patient: with a GnRH antagonist (ANT) and with progesterone. The aim of the study was to find out whether the administration of progesterone in ovarian stimulation treatments could affect oocyte competence.

Gonadotropin stimulation and LH suppression protocols with progesterone (PP) are gaining acceptance over GnRH antagonist (ANT) suppression because they have several attractive aspects: oral administration versus injections, lower cost of medication, and available evidence from comparative studies showing that a similar total number of oocytes and mature oocytes are obtained with PP as with antagonist.

Despite these apparent advantages, a first randomised clinical trial in egg donors reported unexpectedly inferior reproductive outcomes in recipients of oocytes from cycles with PP (medroxyprogesterone) compared to recipients of oocytes from cycles with an antagonist (ANT). Concern was therefore raised about a possible harmful effect of PP on oocytes.

During stimulation treatments, oocytes undergo final maturation through mRNA accumulation and remodelling that will be used after ovulation and fertilisation to support the early stages of embryonic development. The accumulated mRNA becomes available for translation with final maturation. Final maturation is critical for oocyte quality and competence. Oocyte competence is its ability to sustain embryonic development until embryonic genome activation (EGA).

Therefore, Dexeus Mujer considered that a transcriptome study of vitrified mature donor oocytes comparing the effect of LH suppression using PP versus suppression using ANT might be relevant. In total, 22 oocytes (10 ANT oocytes and 12 PP oocytes) from four donors who underwent donor treatment at Dexeus Mujer between January 2017 and March 2018 were analysed.

The analysis of this unique dataset of oocytes from the same patient revealed that the use of progesterone to control LH surge does not significantly alter oocyte gene expression levels compared to the traditional protocol with GnRH antagonists, suggesting similar oocyte competence between the two protocols.

The work has been awarded at the 33rd National Congress of the Spanish Fertility Society held in Bilbao in May this year.

¿Cómo podemos ayudarte?

Te informamos que los datos de carácter personal que proporciones rellenando el presente formulario serán tratados por Fundación Dexeus Mujer como responsable de esta web. La finalidad de la recogida y tratamiento de estos datos es contactar contigo en referencia a tu solicitud y en caso de que expresamente nos autorices enviarte información sobre actividades, promociones y/o servicios y nuestro boletín informativo periódico. La legitimación se realiza a través del consentimiento del interesado. Podrás ejercer tus derechos de acceso, rectificación, limitación y suprimir los datos ante el delegado de protección de datos en así como el derecho a presentar una reclamación ante una autoridad de control. Puedes consultar la información adicional y detallada sobre Protección de Datos en nuestra política de privacidad.

How can we help you?

We inform you that the personal data that you provide by filling in this form will be treated by Dexeus Mujer Foundation as responsible for this website. The purpose of collecting and processing this data is to contact you regarding your request and in the event that you expressly authorize us to send you information on activities, promotions and / or services and our periodic newsletter. The legitimation is carried out through the consent of the interested party. You can exercise your rights of access, rectification, limitation and delete the data before the data protection officer at as well as the right to file a claim with a control authority. You can consult the additional and detailed information on Data Protection in our privacy policy.